Biolitec reports growth during first half of 2012

Biolitec has published its financial results for the first six months of 2012, during which it achieved progress towards its medium-term growth targets.

The company generated group sales of 19.36 million euros (15.37 million pounds) during the first two quarters, up by 2.73 million euros compared to the same period of 2011.

This growth was attributed to rising demand for treatments such as the benign prostate hyperplasia procedure Life and the endoluminal laser treatment for veins ELVeS, while its haemorrhoidal artery therapy HeLP was also successfully launched.

Biolitec expects the continuous enhancement of its installed equipment base will form the basis for dynamic growth.

Chief executive officer Dr Wolfgang Neuberger said: "Our goal in the medium term is to increase the share of revenue in these markets to one-third of our sales and thus, to lay the foundation for further growth adapted to the new conditions in the world market."

Earlier this year, the company launched LHP, a new and almost painless laser procedure for haemorrhoid-related diseases.